Here we found that tumor cell-specific depletion of GR, as well as systemic treatment with the clinical GR antagonist mifepristone, overcame immune evasion and sensitized PDAC tumors to dual ICB in mouse models, leading to tumor growth inhibition and prolonged survival. This evidence concerns the gene NR3C1 and neoplasm.